SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone’s proprietary lead product, ZADAXIN (thymalfasin), may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead, a novel treatment for liver cancer, approved in China, and several other products in late-stage development in China. 

Type
Public
HQ
Foster City, US
Founded
1989
Size (employees)
570 (est)
SciClone Pharmaceuticals was founded in 1989 and is headquartered in Foster City, US
Report incorrect company information

SciClone Pharmaceuticals Office Locations

SciClone Pharmaceuticals has an office in Foster City
Foster City, US (HQ)
900 950 Tower Ln
Show all (1)
Report incorrect company information

SciClone Pharmaceuticals Financials and Metrics

SciClone Pharmaceuticals Financials

SciClone Pharmaceuticals's revenue was reported to be $160.10 m in FY, 2016 which is a 1.8% increase from the previous period.
USD

Revenue (Q2, 2017)

44.5 m

Gross profit (Q2, 2017)

38.9 m

Gross profit margin (Q2, 2017), %

87.3%

Net income (Q2, 2017)

12.2 m

EBIT (Q2, 2017)

12.3 m

Market capitalization (13-Oct-2017)

581.9 m

Closing share price (13-Oct-2017)

11.2

Cash (30-Jun-2017)

157.3 m
SciClone Pharmaceuticals's current market capitalization is $581.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

127.1 m134.8 m157.3 m160.1 m

Revenue growth, %

6%17%2%

Cost of goods sold

22.3 m22.9 m

Gross profit

134.9 m137.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

35.2 m26.6 m32.5 m34.3 m33.6 m37.9 m42.9 m36.5 m39 m40.5 m42.9 m44.5 m

Cost of goods sold

3.8 m4.6 m5 m6 m4.6 m5.7 m6.9 m5.8 m5.7 m5.6 m6.2 m5.7 m

Gross profit

31.4 m22 m27.5 m28.3 m29 m32.3 m36 m30.7 m33.3 m35 m36.7 m38.9 m

Gross profit Margin, %

89%83%85%82%86%85%84%84%85%86%86%87%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

85.8 m86.2 m101.4 m134.4 m

Accounts Receivable

40.3 m

Inventories

15.2 m10.7 m11 m16.6 m

Current Assets

143.4 m140.2 m168.5 m195.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

89.1 m87.5 m87 m96.8 m96 m93 m99.2 m114.7 m117.6 m130.1 m141.3 m157.3 m

Accounts Receivable

32.4 m

Inventories

9.9 m14 m16.3 m14.2 m8.9 m12 m12.1 m12.2 m11.3 m13.8 m15.3 m22 m

Current Assets

136 m136.5 m141.3 m146.7 m140.1 m146.4 m153.8 m162.2 m167.7 m184.2 m207.1 m231 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

11 m25.2 m29.5 m30.7 m

Depreciation and Amortization

860 k852 k931 k985 k

Inventories

(4.7 m)5.9 m1.4 m(3 m)

Accounts Payable

(652 k)(5.5 m)(2.3 m)(3.1 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

8.7 m4.1 m9.6 m7.9 m9 m(4 m)12 m7.9 m6.3 m10.1 m14.6 m

Inventories

16.3 m14.2 m8.9 m12 m12.1 m12.2 m11.3 m13.8 m15.3 m

Accounts Payable

6.6 m6.4 m2.4 m5.4 m3.8 m3.3 m2.6 m4.7 m2 m
USDY, 2017

Revenue/Employee

78.1 k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information